Ikuyama S, Nawata H, Kato K, Karashima T, Ibayashi H, Nakagaki H
J Clin Endocrinol Metab. 1985 Oct;61(4):666-71. doi: 10.1210/jcem-61-4-666.
Specific somatostatin (SRIH) receptors on human pituitary adenoma cell membranes were characterized using [125I]Tyr11-SRIH as the radioligand. Specific binding of [125I] Tyr11-SRIH to adenoma cell membranes reached a steady state within 30 min at 25 C, and semilogarithmic analysis of the data revealed that the rate of the binding was linear at 25 C with a t1/2 of 13.2 min. Specific binding increased linearly with 5-160 micrograms plasma membrane protein. SRIH-14 and SRIH-28 inhibited [125I]Tyr11-SRIH binding to adenoma cell membranes with ID50S of 0.32 and 0.50 nM, respectively, while secretin, glucagon, gastrin, cholecystokinin-8, bombesin, TRH, LHRH, human GH-releasing factor-(1-44)-NH2, D-Ala2-met-enkephalin, gamma-aminobutyric acid and taurine did not significantly inhibit binding. All of 13 GH-secreting adenomas investigated had specific and high affinity SRIH receptors, with a dissociation constant (Kd) of 0.80 +/- 0.15 nM (mean +/- SEM) and a maximal binding capacity (Bmax) of 234.2 +/- 86.9 fmol/mg protein (mean +/- SEM). Among five of the nonsecreting pituitary adenomas examined, two had SRIH receptors with Kd values of 0.18 and 0.32 nM and Bmax values of 17.2 and 48.0 fmol/mg protein, respectively. In the remaining three, SRIH receptors were not detected. These results indicate that GH-secreting adenomas as well as some nonfunctioning adenomas have specific SRIH receptors, and hence, the function of the adenomas could be altered by SRIH.
利用[125I]Tyr11-生长抑素(SRIH)作为放射性配体,对人垂体腺瘤细胞膜上的特异性生长抑素(SRIH)受体进行了表征。在25℃下,[125I]Tyr11-SRIH与腺瘤细胞膜的特异性结合在30分钟内达到稳态,对数据的半对数分析表明,在25℃下结合速率呈线性,t1/2为13.2分钟。特异性结合随5-160微克质膜蛋白呈线性增加。SRIH-14和SRIH-28抑制[125I]Tyr11-SRIH与腺瘤细胞膜的结合,ID50分别为0.32和0.50 nM,而促胰液素、胰高血糖素、胃泌素、胆囊收缩素-8、蛙皮素、促甲状腺激素释放激素(TRH)、促黄体生成素释放激素(LHRH)、人生长激素释放因子-(1-44)-NH2、D-Ala2-甲硫氨酸脑啡肽、γ-氨基丁酸和牛磺酸均未显著抑制结合。所研究的13例生长激素分泌型腺瘤均具有特异性和高亲和力的SRIH受体,解离常数(Kd)为0.80±0.15 nM(平均值±标准误),最大结合容量(Bmax)为234.2±86.9 fmol/mg蛋白(平均值±标准误)。在所检查的5例无分泌功能的垂体腺瘤中,2例具有SRIH受体,Kd值分别为0.18和0.32 nM,Bmax值分别为17.2和48.0 fmol/mg蛋白。在其余3例中,未检测到SRIH受体。这些结果表明,生长激素分泌型腺瘤以及一些无功能腺瘤具有特异性SRIH受体,因此,SRIH可改变腺瘤的功能。